Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2017 Q1- Text added to 2017 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Good
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Good
|
New words:
amatuximab, announce, archival, arginine, Bavencio, claudiximab, composite, confirmed, Darmstadt, degrading, disaster, edema, Eli, enzyme, escalation, eyelid, FGF, fourteen, GEJ, Genentech, giant, GmbH, hyperphosphatemia, Imfinzi, ImfinziTM, Immunotherapy, inclusion, Japanese, KGaA, landlord, leasehold, median, Morphotek, objective, ocular, OFEV, optimize, passed, PD, periorbital, Pfizer, poster, radiographic, rash, RECIST, refine, rejected, rent, retinal, sample, score, Senate, skinny, solid, taper, tenosynovial, tentative, tissue, toxicity, UK, unconfirmed, urothelial, version
Removed:
accurately, addressed, arrested, Attorney, BIBF, collaborator, faster, GBM, informed, refractory, restricted, theft
Valuein 2017 Q1 filing- Value in 2017 Q2 filing
Original filings
Filing view